In operation own data and analytical arguing about possibility of application replacement hormonal of therapy (RHT) Livial at patients with climacteric cardiopathies are represented. In an outcome of researches is installed, that Livial promotes improving systole of myocard and reduces a degree it hypertrophy; normalization intracardial and intravascular bloodstream, improving active activw relaxing of the left ventricle and rise of elasticity large arterys. The tendency to normalization, and on early stages climacteric climacteric hypertension - normalization arterial of pressure, and also - improving trofics of the myocard, rise of its electrical stability and lowering arithmogenic is observed; an amplification anticoagulation and lowering procoagulation of a potential of blood with improving oj microcirculation. Obtained data specify validity and necessity RHT of Livial at the women with climacteric cardiopathies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.